{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:16Z","timestamp":1780470196287,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-002"],"award-info":[{"award-number":["2021-I2M-C&T-B-002"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-028"],"award-info":[{"award-number":["2022-PUMCH-C-028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02239-5","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:02:14Z","timestamp":1704960134000},"page":"1191-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel alternative tools for metastatic pheochromocytomas\/paragangliomas prediction"],"prefix":"10.1007","volume":"47","author":[{"given":"Y.","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-6551","authenticated-orcid":false,"given":"X.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-7540","authenticated-orcid":false,"given":"A.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"12","key":"2239_CR1","first-page":"802","volume":"58","author":"CM Beard","year":"1983","unstructured":"Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT (1983) Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58(12):802\u2013804","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2239_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2239_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK Lam","year":"2017","unstructured":"Lam AK (2017) Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours. Endocr Pathol 28(3):213\u2013227. https:\/\/doi.org\/10.1007\/s12022-017-9484-5","journal-title":"Endocr Pathol"},{"issue":"3","key":"2239_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"Eisenhofer G, Bornstein SR, Brouwers FM et al (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11(3):423\u2013436. https:\/\/doi.org\/10.1677\/erc.1.00829","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2239_CR5","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L et al (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(10):4006\u20134012. https:\/\/doi.org\/10.1210\/jc.2013-1907","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2239_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4158\/ep15725.Or","volume":"22","author":"H Turkova","year":"2016","unstructured":"Turkova H, Prodanov T, Maly M et al (2016) Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study. Endocr Pract 22(3):302\u2013314. https:\/\/doi.org\/10.4158\/ep15725.Or","journal-title":"Endocr Pract"},{"issue":"17","key":"2239_CR7","first-page":"5615","volume":"63","author":"AP Gimenez-Roqueplo","year":"2003","unstructured":"Gimenez-Roqueplo AP, Favier J, Rustin P et al (2003) Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas. Cancer Res 63(17):5615\u20135621","journal-title":"Cancer Res"},{"issue":"31","key":"2239_CR8","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1200\/jco.2011.34.6353","volume":"29","author":"KS King","year":"2011","unstructured":"King KS, Prodanov T, Kantorovich V et al (2011) Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29(31):4137\u20134142. https:\/\/doi.org\/10.1200\/jco.2011.34.6353","journal-title":"J Clin Oncol"},{"key":"2239_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-14-523","volume":"14","author":"J Schovanek","year":"2014","unstructured":"Schovanek J, Martucci V, Wesley R et al (2014) The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer 14:523. https:\/\/doi.org\/10.1186\/1471-2407-14-523","journal-title":"BMC Cancer"},{"issue":"9","key":"2239_CR10","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, I\u00f1iguez-Ariza NM et al (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55\u00a0years. J Clin Endocrinol Metab 102(9):3296\u20133305. https:\/\/doi.org\/10.1210\/jc.2017-00992","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2239_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM et al (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717\u2013725. https:\/\/doi.org\/10.1210\/jc.2010-1946","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2239_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","volume":"41","author":"T Zelinka","year":"2011","unstructured":"Zelinka T, Musil Z, Du\u0161kov\u00e1 J et al (2011) Metastatic pheochromocytoma: does the size and age matter? Eur J Clin Invest 41(10):1121\u20131128. https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02518.x","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"2239_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","volume":"164","author":"YY Cho","year":"2018","unstructured":"Cho YY, Kwak MK, Lee SE et al (2018) A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery 164(3):511\u2013517. https:\/\/doi.org\/10.1016\/j.surg.2018.05.001","journal-title":"Surgery"},{"issue":"6","key":"2239_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.surg.2008.02.007","volume":"143","author":"VE Strong","year":"2008","unstructured":"Strong VE, Kennedy T, Al-Ahmadie H et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle\/apoptosis gene expression analysis. Surgery 143(6):759\u2013768. https:\/\/doi.org\/10.1016\/j.surg.2008.02.007","journal-title":"Surgery"},{"issue":"1","key":"2239_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-2559.2003.01645.x","volume":"43","author":"K Salmenkivi","year":"2003","unstructured":"Salmenkivi K, Heikkil\u00e4 P, Haglund C, Louhimo J, Arola J (2003) Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology 43(1):62\u201371. https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01645.x","journal-title":"Histopathology"},{"issue":"5","key":"2239_CR16","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.juro.2010.12.050","volume":"185","author":"F Feng","year":"2011","unstructured":"Feng F, Zhu Y, Wang X et al (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185(5):1583\u20131590. https:\/\/doi.org\/10.1016\/j.juro.2010.12.050","journal-title":"J Urol"},{"issue":"11","key":"2239_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JW, Siegert G et al (2012) Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48(11):1739\u20131749. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016","journal-title":"Eur J Cancer"},{"issue":"5","key":"2239_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/erc-19-0024","volume":"26","author":"J Crona","year":"2019","unstructured":"Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K (2019) Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocr Relat Cancer 26(5):539\u2013550. https:\/\/doi.org\/10.1530\/erc-19-0024","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2239_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson LD (2002) Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551\u2013566. https:\/\/doi.org\/10.1097\/00000478-200205000-00002","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2239_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/erc-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N et al (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21(3):405\u2013414. https:\/\/doi.org\/10.1530\/erc-13-0494","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2239_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H et al (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS ONE 12(11):e0187398. https:\/\/doi.org\/10.1371\/journal.pone.0187398","journal-title":"PLoS ONE"},{"issue":"6","key":"2239_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L et al (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474(6):721\u2013734. https:\/\/doi.org\/10.1007\/s00428-019-02553-5","journal-title":"Virchows Arch"},{"issue":"8","key":"2239_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/s1470-2045(09)70164-0","volume":"10","author":"FH van Nederveen","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10(8):764\u2013771. https:\/\/doi.org\/10.1016\/s1470-2045(09)70164-0","journal-title":"Lancet Oncol"},{"issue":"4","key":"2239_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jmedgenet-2019-106324","volume":"57","author":"H Lee","year":"2020","unstructured":"Lee H, Jeong S, Yu Y et al (2020) Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis. J Med Genet 57(4):217\u2013225. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106324","journal-title":"J Med Genet"},{"key":"2239_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.68436","author":"X Zhang","year":"2021","unstructured":"Zhang X, Lian P, Su M et al (2021) Single-cell transcriptome analysis identifies a unique tumor cell type producing multiple hormones in ectopic ACTH and CRH secreting pheochromocytoma. Elife. https:\/\/doi.org\/10.7554\/eLife.68436","journal-title":"Elife"},{"issue":"5","key":"2239_CR26","first-page":"484","volume":"115","author":"P Unger","year":"1991","unstructured":"Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M (1991) S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115(5):484\u2013487","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2239_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1385\/ep:13:2:149","volume":"13","author":"N Kumaki","year":"2002","unstructured":"Kumaki N, Kajiwara H, Kameyama K et al (2002) Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr Pathol Summer 13(2):149\u2013156. https:\/\/doi.org\/10.1385\/ep:13:2:149","journal-title":"Endocr Pathol Summer"},{"issue":"2","key":"2239_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1078-0432.Ccr-18-0139","volume":"25","author":"S Job","year":"2019","unstructured":"Job S, Draskovic I, Burnichon N et al (2019) Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 25(2):760\u2013770. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0139","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2239_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.Ccr-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi AD, Liu TC, Roncaioli JL et al (2017) Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res 23(2):600\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1113","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2239_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz115","volume":"56","author":"YR Hsu","year":"2019","unstructured":"Hsu YR, Torres-Mora J, Kipp BR et al (2019) Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas\u2020. Eur J Cardiothorac Surg 56(5):867\u2013875. https:\/\/doi.org\/10.1093\/ejcts\/ezz115","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"2239_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/pas.0000000000000324","volume":"39","author":"JY Liau","year":"2015","unstructured":"Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH, Yang CY (2015) Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am J Surg Pathol 39(2):236\u2013244. https:\/\/doi.org\/10.1097\/pas.0000000000000324","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2239_CR32","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.humpath.2015.05.019","volume":"46","author":"JY Liau","year":"2015","unstructured":"Liau JY, Tsai JH, Yang CY et al (2015) Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas. Hum Pathol 46(9):1360\u20131366. https:\/\/doi.org\/10.1016\/j.humpath.2015.05.019","journal-title":"Hum Pathol"},{"key":"2239_CR33","doi-asserted-by":"publisher","unstructured":"Zhou Y 2023 Data from: Novel alternative tools for metastatic pheochromocytomas\/paragangliomas prediction. https:\/\/doi.org\/10.7910\/DVN\/HWBD74","DOI":"10.7910\/DVN\/HWBD74"},{"issue":"5","key":"2239_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"2","key":"2239_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"N\u00f6lting S, Bechmann N, Taieb D et al (2022) Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43(2):199\u2013239. https:\/\/doi.org\/10.1210\/endrev\/bnab019","journal-title":"Endocr Rev"},{"key":"2239_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.762548","volume":"12","author":"Y Cui","year":"2021","unstructured":"Cui Y, Ma X, Gao Y et al (2021) Local-regional recurrence of pheochromocytoma\/paraganglioma: characteristics, risk factors and outcomes. Front Endocrinol (Lausanne) 12:762548. https:\/\/doi.org\/10.3389\/fendo.2021.762548","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2239_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026567","author":"MA Dyer","year":"2017","unstructured":"Dyer MA, Qadeer ZA, Valle-Garcia D, Bernstein E (2017) ATRX and DAXX: Mechanisms and mutations. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026567","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"2239_CR38","first-page":"2072","volume":"7","author":"CY Yang","year":"2015","unstructured":"Yang CY, Liau JY, Huang WJ et al (2015) Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma. Am J Transl Res 7(10):2072\u20132081","journal-title":"Am J Transl Res"},{"key":"2239_CR39","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1038\/ncomms7140","volume":"6","author":"L Fishbein","year":"2015","unstructured":"Fishbein L, Khare S, Wubbenhorst B et al (2015) Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 6:6140. https:\/\/doi.org\/10.1038\/ncomms7140","journal-title":"Nat Commun"},{"issue":"6041","key":"2239_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041):425. https:\/\/doi.org\/10.1126\/science.1207313","journal-title":"Science"},{"issue":"2","key":"2239_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ijo.2013.1963","volume":"43","author":"M Pacurari","year":"2013","unstructured":"Pacurari M, Addison JB, Bondalapati N et al (2013) The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 43(2):548\u2013560. https:\/\/doi.org\/10.3892\/ijo.2013.1963","journal-title":"Int J Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02239-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02239-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02239-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:24:36Z","timestamp":1713770676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02239-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02239-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"2 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest, we do not have any possible conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committees of Peking Union Medical College Hospital (JS-3535).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}